Impact of long-term exposure to ambient ozone on lung function over a course of 20 years (The ECRHS study): a prospective cohort study in adults.

Background: While the adverse effects of short-term ambient ozone exposure on lung function are well-documented, the impact of long-term exposure remains poorly understood, especially in adults. Methods: We aimed to investigate the association between long-term ozone exposure and lung function decline. The 3014 participants were drawn from 17 centers across eight countries, all of which were from the European Community Respiratory Health Survey (ECRHS). Spirometry was conducted to measure pre-bronchodilation forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) at approximately 35, 44, and 55 years of age. We assigned annual mean values of daily maximum running 8-h average ozone concentrations to individual residential addresses. Adjustments were made for PM2.5, NO2, and greenness. To capture the ozone-related change in spirometric parameters, our linear mixed effects regression models included an interaction term between long-term ozone exposure and age. Findings: Mean ambient ozone concentrations were approximately 65 µg/m³. A one interquartile range increase of 7 µg/m³ in ozone was associated with a faster decline in FEV1 of -2.08 mL/year (95% confidence interval: -2.79, -1.36) and in FVC of -2.86 mL/year (-3.73, -1.99) mL/year over the study period. Associations were robust after adjusting for PM2.5, NO2, and greenness. The associations were more pronounced in residents of northern Europe and individuals who were older at baseline. No consistent associations were detected with the FEV1/FVC ratio. Interpretation: Long-term exposure to elevated ambient ozone concentrations was associated with a faster decline of spirometric lung function among middle-aged European adults over a 20-year period. Funding: German Research Foundation.

Residential greenspace and lung function decline over 20 years in a prospective cohort: The ECRHS study.

BACKGROUND: The few studies that have examined associations between greenspace and lung function in adulthood have yielded conflicting results and none have examined whether the rate of lung function decline is affected. OBJECTIVE: We explored the association between residential greenspace and change in lung function over 20 years in 5559 adults from 22 centers in 11 countries participating in the population-based, international European Community Respiratory Health Survey. METHODS: Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured by spirometry when participants were approximately 35 (1990-1994), 44 (1999-2003), and 55 (2010-2014) years old. Greenness was assessed as the mean Normalized Difference Vegetation Index (NDVI) in 500 m, 300 m, and 100 m circular buffers around the residential addresses at the time of lung function measurement. Green spaces were defined as the presence of agricultural, natural, or urban green spaces in a circular 300 m buffer. Associations of these greenspace parameters with the rate of lung function change were assessed using adjusted linear mixed effects regression models with random intercepts for subjects nested within centers. Sensitivity analyses considered air pollution exposures. RESULTS: A 0.2-increase (average interquartile range) in NDVI in the 500 m buffer was consistently associated with a faster decline in FVC (-1.25 mL/year [95% confidence interval: -2.18 to -0.33]). These associations were especially pronounced in females and those living in areas with low PM10 levels. We found no consistent associations with FEV1 and the FEV1/FVC ratio. Residing near forests or urban green spaces was associated with a faster decline in FEV1, while agricultural land and forests were related to a greater decline in FVC. CONCLUSIONS: More residential greenspace was not associated with better lung function in middle-aged European adults. Instead, we observed slight but consistent declines in lung function parameters. The potentially detrimental association requires verification in future studies.

Oxigenoterapia domiciliaria en enfermedades pulmonares Restrictivas (neumopatías intersticiales en general) Y al esfuerzo enpacientes sin insuficiencia Respiratoria crónica / No disponible

No disponible

[Asthma incidence in Huelva, Spain at 2 stages of life: childhood and young adulthood]. / Incidencia de asma en 2 etapas de la vida: niños y adultos jóvenes de la ciudad de Huelva.

OBJECTIVE: Few studies have evaluated the incidence of asthma in Spain. Although more children than adults develop asthma every year, no study to date has analyzed the differences in incidence by following 2 age cohorts in the same geographical area. The aim of this study was to determine changes in wheezing, bronchial hyperreactivity, and asthma (in terms of onset, persistence, and remission), changes in forced expiratory volume in 1 second (FEV(1)), and asthma incidence in children (11-16 years) and young adults (20-44 years) in the city of Huelva, Spain. PATIENTS AND METHODS: We analyzed data from 2 groups studied for the first time between 1991 and 1993 and for the second time after an average follow-up period of 9 years. In the first period, data came from the Study of Respiratory Diseases in Huelva (714 children) and the European Community Respiratory Health Survey conducted in the city (271 adults). Both groups answered a respiratory symptom questionnaire, underwent spirometry testing, and completed a nonspecific bronchial challenge test with methacholine. RESULTS: In adults, onset was more common than remission for both wheezing (15.7% vs 6.9%, P=.011) and bronchial hyperreactivity (10.1% vs 3%, P=.017), and asthma incidence was 4.76 cases/1000 person-years. In children, there were more new cases than remissions for wheezing, (24.2% vs 4.3%, P=.001), bronchial hyperreactivity (13.9% vs 5.4%, P=.02), and asthma (9.3% vs 3%, P=.004). The incidence rate for asthma was 15.69 cases/1000 person-years in this age group. The annual decrease in lung function (FEV(1)) was highest in adults with wheezing (34.3 mL) and asthma (54.8 mL). CONCLUSIONS: There were more new cases of wheezing and bronchial hyperreactivity than remissions in both children and young adults. Children had a 3.3-fold higher incidence of asthma than adults in Huelva.

Incidencia de asma en 2 etapas de la vida: niños y adultos jóvenes de la ciudad de Huelva / Asthma incidence in Huelva, Spain at 2 stages of life: childhood and young adulthood

OBJETIVO: Hay pocos estudios que valoren la incidencia de asma en nuestro país. Se sabe que es mayor en niños que en adultos, pero esta diferente incidencia no se ha comprobado mediante el seguimiento de 2 poblaciones de diferente edad en el mismo ámbito geográfico. El propósito de este trabajo ha sido determinar los cambios (aparición, persistencia y remisión) de sibilancias, hiperreactividad bronquial (HB) y asma, la evolución del volumen espiratorio forzado en el primer segundo y la incidencia anual de asma en niños (11-16 años) y adultos jóvenes (20-44 años) en la ciudad de Huelva. PACIENTES Y MÉTODOS: Se ha realizado una segunda evaluación en el seguimiento de 2 grupos estudiados entre 1991 y 1993 (714 niños del Estudio de Enfermedades Respiratorias de Huelva y 271 adultos del Estudio Europeo de Enfermedades Respiratorias), con un promedio de tiempo de 9 años. Se pasó a ambos grupos un cuestionario sobre síntomas respiratorios, además de efectuar una espirometría y una prueba de provocación bronquial inespecífica con metacolina. RESULTADOS: En los adultos se encontraron más nuevas apariciones (15,7%) que remisiones (6,9%) de sibilancias (p = 0,011) e HB (apariciones: 10,1%; remisiones: 3%; p = 0,017), con una incidencia anual de asma de 4,76 casos/1.000 personas-año. Los niños mostraron más nuevas apariciones (24,2%) que remisiones (4,3%) de sibilancias (p < 0,001), HB (un 13,9% de apariciones y un 5,4% de remisiones; p = 0,02) y asma (un 9,3% de apariciones y un 3% de remisiones; p = 0,004), con una incidencia anual de asma de 15,69 casos/1.000 personas-año. La pérdida anual de función pulmonar (volumen espiratorio forzado en el primer segundo) fue más elevada en los adultos en los que aparecieron sibilancias (34,3 ml) y asma (54,8 ml). CONCLUSIONES: En ambas poblaciones, hay más nuevos casos de sibilancias e HB que remisiones. La incidencia anual de asma es 3,3 veces mayor en niños que en adultos en la ciudad de Huelva

OBJECTIVE: Few studies have evaluated the incidence of asthma in Spain. Although more children than adults develop asthma every year, no study to date has analyzed the differences in incidence by following 2 age cohorts in the same geographical area. The aim of this study was to determine changes in wheezing, bronchial hyperreactivity, and asthma (in terms of onset, persistence, and remission), changes in forced expiratory volume in 1 second (FEV1), and asthma incidence in children (11-16 years) and young adults (20-44 years) in the city of Huelva, Spain. PATIENTS AND METHODS: We analyzed data from 2 groups studied for the first time between 1991 and 1993 and for the second time after an average follow-up period of 9 years. In the first period, data came from the Study of Respiratory Diseases in Huelva (714 children) and the European Community Respiratory Health Survey conducted in the city (271 adults). Both groups answered a respiratory symptom questionnaire, underwent spirometry testing, and completed a nonspecific bronchial challenge test with methacholine. RESULTS: In adults, onset was more common than remission for both wheezing (15.7% vs 6.9%, P=.011) and bronchial hyperreactivity (10.1% vs 3%, P=.017), and asthma incidence was 4.76 cases/1000 person-years. In children, there were more new cases than remissions for wheezing, (24.2% vs 4.3%, P=.001), bronchial hyperreactivity (13.9% vs 5.4%, P=.02), and asthma (9.3% vs 3%, P=.004). The incidence rate for asthma was 15.69 cases/1000 person-years in this age group. The annual decrease in lung function (FEV1) was highest in adults with wheezing (34.3 mL) and asthma (54.8 mL). CONCLUSIONS: There were more new cases of wheezing and bronchial hyperreactivity than remissions in both children and young adults. Children had a 3.3-fold higher incidence of asthma than adults in Huelva

Bronchial hyperreactivity in patients who inhale heroin mixed with cocaine vaporized on aluminum foil.

BACKGROUND: In our area, inhaling heroin mixed with cocaine vaporized on aluminum foil, known as rebujo, is becoming more and more common. AIM: To define the prevalence and the characteristics of bronchial disease (wheezing, bronchial hyperreactivity [BHR], and asthma) present in subjects inhaling heroin mixed with cocaine vaporized on aluminum foil. MATERIALS AND METHODS: Ninety-one subjects who inhaled the drug mixture were included in the study: 62 subjects were from a drug rehabilitation center (INH-I group), and 29 subjects were among patients admitted to our hospital for a variety of reasons (INH-II group). A questionnaire was completed in both groups, as well as IgE determination and lung function tests (spirometry and methacholine challenge). The control group consisted of 122 individuals who did not inhale the drug mixture, and were chosen randomly from the general population (NO-INH group). All subjects were tobacco smokers. RESULTS: In the INH-I group, there was a 41.9% prevalence of wheezing over the past 12 months, a 44.4% prevalence of BHR, and a 22.02% prevalence of asthma, defined as wheezing plus BHR. In the NO-INH group, these values were 32.78% (p = 0.22), 15.57% (p < 0.0001), and 8.19% (p < 0.01), respectively. Of the subjects who inhaled the drug mixture and denied having symptoms prior to the use of the drug mixture, 31.4% had wheezing develop after commencing use of the drug, following a mean latency of 4.09 months. Wheezing remitted in only 7.6% after discontinuation of the drug. CONCLUSIONS: (1) There is a real increase in BHR in subjects who inhale heroin mixed with cocaine vaporized on aluminum foil; and (2) this BHR is associated with wheezing that develops after a variable period of latency, once drug inhalation begins, and persists despite discontinuation of the drug.